Top 1% Biotech Crashes, Wiping Out A Run, On A Serious Side Effect

By Investor's Business Daily | Nov 12, 2024 at 10:18 AM EST

Biotech stock Neurogene (NGNE) plunged after a patient in their Rett syndrome study had a serious side effect. The adverse event is linked to gene therapy side effects but doesn't affect Neurogene's platform. Stock dropped over 40%, erasing recent gains.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.